March 1, 2016
Affygility Solutions, a provider of OEL Fastrac™ for the life sciences industry, announced today that Frank Richardson, DVM, PhD, DABT, a toxicology professional with nearly 30 years experience, has joined the company as a Principal Toxicologist. Dr. Richardson will provide toxicology consulting services to Affygility Solutions’ rapidly growing list of biotechnology, pharmaceutical, and medical device clients.
Prior to joining Affygility Solutions, Dr. Richardson was a Principle Research Fellow, Safety Assessment and Molecular Markers, for OSI Pharmaceuticals. Additional prior work included positions at Gilead Sciences, NexStar Pharmaceuticals, Eli Lilly and Company, and the Chemical Industries Institute of Toxicology.
Dr. Richardson is a Diplomat of the American Board of Toxicology (DABT) and received a Ph.D. in Experimental Pathology from Duke University, a D.V.M. from Iowa State University, and a B.S. degree from the Massachusetts Institute of Technology.
Dr. Richardson has published over 50 peer-reviewed scientific articles in prominent journals such as Cancer Research, Carcinogenesis, Clinical Oncology, Environmental Health Perspectives, Chemical Research in Toxicology, the New England Journal of Medicine, and Proceedings of the National Academy of Sciences.
“We are extremely excited to have Frank joining our team of occupational health, safety, and toxicology professionals,” said Dean M. Calhoun, CIH, President and Chief Executive Officer of Affygility Solutions. “Having personally known and worked with Frank for over 19 years, I am confident his wealth of toxicology and pharmaceutical industry experience will provide significant value to the potent compound safety services we offer to our worldwide life science clients.”
Press release: Dr. Frank Richardson joins Affygility Solutions (72kb)